1. Home
  2. MDXH vs PMI Comparison

MDXH vs PMI Comparison

Compare MDXH & PMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MDxHealth SA

MDXH

MDxHealth SA

HOLD

Current Price

$3.42

Market Cap

183.4M

Sector

N/A

ML Signal

HOLD

PMI

Picard Medical Inc.

N/A

Current Price

$1.53

Market Cap

202.7M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
MDXH
PMI
Founded
2003
1981
Country
Belgium
United States
Employees
N/A
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
183.4M
202.7M
IPO Year
2021
2025

Fundamental Metrics

Financial Performance
Metric
MDXH
PMI
Price
$3.42
$1.53
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$7.67
N/A
AVG Volume (30 Days)
123.5K
1.9M
Earning Date
02-26-2026
03-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$103,069,000.00
$4,767,000.00
Revenue This Year
$23.34
N/A
Revenue Next Year
$22.98
N/A
P/E Ratio
N/A
N/A
Revenue Growth
21.68
8.81
52 Week Low
$1.35
$1.30
52 Week High
$5.33
$13.68

Technical Indicators

Market Signals
Indicator
MDXH
PMI
Relative Strength Index (RSI) 44.64 35.38
Support Level $3.45 $1.30
Resistance Level $3.80 $2.50
Average True Range (ATR) 0.20 0.24
MACD -0.02 -0.01
Stochastic Oscillator 5.00 9.17

Price Performance

Historical Comparison
MDXH
PMI

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

About PMI Picard Medical Inc.

Picard Medical Inc operates through its wholly owned subsidiary, a medical technology company focused on developing, manufacturing, and commercializing an implantable Total Artificial Heart. It is engaged in designing, manufacturing, producing, supplying, marketing, and selling medical device products, including TAH. The TAH is an implantable system designed to assume the full function of a failed human heart in patients suffering from advanced heart failure.

Share on Social Networks: